PR

Prophase Labs IncNASDAQ PRPH Stock Report

Last reporting period 30 Jun, 2024

Updated 14 Nov, 2024

Last price

Market cap $B

0.042

Micro

Exchange

XNAS - Nasdaq

PRPH Stock Analysis

PR

Uncovered

Prophase Labs Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-56/100

Low score

Market cap $B

0.042

Dividend yield

7.08 %

Shares outstanding

16.278 B

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The company is headquartered in New York City, New York and currently employs 129 full-time employees. The firm operates through two segments: diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services. The firm is also engaged in the development and marketing of dietary supplements under the TK Supplements brand. The Company’s TK Supplements product line includes Legendz XL, a male sexual enhancement and Triple Edge XL, an energy and stamina booster.

View Section: Eyestock Rating